{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T02:55:59Z","timestamp":1767927359962,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005722","name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ejca.2022.07.012","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T19:33:50Z","timestamp":1660332830000},"page":"297-306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0\/1 resection of RAS wild-type colorectal cancer liver metastases \u2013 The PARLIM trial (AIO KRK 0314)"],"prefix":"10.1016","volume":"173","author":[{"given":"Dominik Paul","family":"Modest","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meinolf","family":"Karthaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Moosmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Keitel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Kiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Uhlig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lutz","family":"Jacobasch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludwig","family":"Fischer v. Weikersthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Lerchenm\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"Sent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Junghan\u00df","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swantje","family":"Held","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Lorenzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Kaczirek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Stintzing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.07.012_bib1","article-title":"Ten-year survival after liver resection for colorectal metastases: systematic review and meta-analysis","volume":"2011","author":"Abbas","year":"2011","journal-title":"ISRN Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2022.07.012_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1477-2574.2012.00597.x","article-title":"Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements","volume":"15","author":"Abdalla","year":"2013","journal-title":"HPB"},{"issue":"22","key":"10.1016\/j.ejca.2022.07.012_bib3","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1200\/JCO.2008.20.5278","article-title":"Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy","volume":"27","author":"Kopetz","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2022.07.012_bib4","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.07.012_bib5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejca.2017.10.028","article-title":"Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3","volume":"88","author":"Modest","year":"2018","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2022.07.012_bib6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1470-2045(09)70330-4","article-title":"Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial","volume":"11","author":"Folprecht","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.07.012_bib7","article-title":"Factors that influence conversion to resectability and survival after resection of metastases in RAS WT metastatic colorectal cancer (mCRC): analysis of FIRE-3- AIOKRK0306","author":"Modest","year":"2020","journal-title":"Ann Surg Oncol. 2020 Jul;27(7):2389-2401."},{"issue":"9617","key":"10.1016\/j.ejca.2022.07.012_bib8","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0140-6736(08)60455-9","article-title":"Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial","volume":"371","author":"Nordlinger","year":"2008","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ejca.2022.07.012_bib9","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S1470-2045(13)70447-9","article-title":"Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial","volume":"14","author":"Nordlinger","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.07.012_bib10","article-title":"Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial","author":"Primrose","year":"2014","journal-title":"Lancet Oncol. 2014 May;15(6):601-11"},{"issue":"30","key":"10.1016\/j.ejca.2022.07.012_bib11","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1200\/JCO.2008.17.3781","article-title":"Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials","volume":"26","author":"Mitry","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.07.012_bib12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2016.10.028","article-title":"Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: a pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest","volume":"73","author":"Cremolini","year":"2017","journal-title":"Eur J Cancer"},{"issue":"35","key":"10.1016\/j.ejca.2022.07.012_bib13","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.19.01340","article-title":"FOLFOXIRI plus panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer: the randomized, open-label, phase II VOLFI study (AIO KRK0109)","volume":"37","author":"Modest","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.07.012_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.sla.0000193603.26265.c3","article-title":"Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases","volume":"243","author":"Karoui","year":"2006","journal-title":"Ann Surg"},{"issue":"34","key":"10.1016\/j.ejca.2022.07.012_bib15","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1200\/JCO.21.01032","article-title":"Hepatectomy followed by mFOLFOX6 versus hepatectomy alone for liver-only metastatic colorectal cancer (JCOG0603): a phase II or III randomized controlled trial","volume":"39","author":"Kanemitsu","year":"2021","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2022.07.012_bib16","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of adjuvant chemotherapy for stage III colon cancer","volume":"378","author":"Grothey","year":"2018","journal-title":"N Engl J Med"},{"issue":"31","key":"10.1016\/j.ejca.2022.07.012_bib17","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ejca.2022.07.012_bib18","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2013.53.2473","volume":"32","author":"Schwartzberg","year":"2014","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1016\/j.ejca.2022.07.012_bib19","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1200\/JCO.21.01332","article-title":"Panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer: the randomized Panama trial (AIO KRK 0212)","volume":"40","author":"Modest","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2022.07.012_bib20","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jamaoncol.2019.1467","article-title":"Maintenance therapy with panitumumab alone vs panitumumab plus fluorouracil-leucovorin in patients with RAS wild-type metastatic colorectal cancer: a phase 2 randomized clinical trial","volume":"5","author":"Pietrantonio","year":"2019","journal-title":"JAMA Oncol."},{"issue":"18","key":"10.1016\/j.ejca.2022.07.012_bib21","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2022.07.012_bib22","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/annonc\/mdu088","article-title":"Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX\/cetuximab or FOLFIRI\/cetuximab in a multidisciplinary concept (CELIM study)","volume":"25","author":"Folprecht","year":"2014","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2022.07.012_bib23","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S1470-2045(16)30269-8","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial","volume":"17","author":"Stintzing","year":"2016","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2022.07.012_bib24","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1055\/s-0043-121106","article-title":"S3-Leitlinie \u2013 Kolorektales Karzinom","volume":"55","author":"Schmiegel","year":"2017","journal-title":"Z Gastroenterol"},{"issue":"8","key":"10.1016\/j.ejca.2022.07.012_bib25","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S1470-2045(14)70227-X","article-title":"Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial","volume":"15","author":"Taieb","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.07.012_bib26","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejca.2020.07.031","article-title":"A new prognostic and predictive tool for shared decision making in stage III colon cancer","volume":"138","author":"Sobrero","year":"2020","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2022.07.012_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003620","article-title":"Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: a prospective cohort study","volume":"18","author":"Tie","year":"2021","journal-title":"PLoS Med"},{"issue":"6","key":"10.1016\/j.ejca.2022.07.012_bib28","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.20.01330","article-title":"Duration of adjuvant doublet chemotherapy (3 or 6 months) in patients with high-risk stage II colorectal cancer","volume":"39","author":"Iveson","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2022.07.012_bib29","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1080\/0284186X.2020.1806357","article-title":"Circulating tumor DNA as a marker of minimal residual disease following local treatment of metastases from colorectal cancer","volume":"59","author":"Boysen","year":"2020","journal-title":"Acta Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2022.07.012_bib30","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ejca.2015.01.054","article-title":"Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis","volume":"51","author":"Pietrantonio","year":"2015","journal-title":"Eur J Cancer"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2022.07.012_bib31","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.2021.39.15_suppl.3502","article-title":"Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: the phase-II FIRE-4.5 study (AIO KRK-0116)","volume":"39","author":"Stintzing","year":"2021","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.ejca.2022.07.012_bib32","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1200\/JCO.19.01254","article-title":"Negative Hyperselection of patients with RAS and BRAF wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy","volume":"37","author":"Morano","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922004282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922004282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:37:00Z","timestamp":1762342620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922004282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":32,"alternative-id":["S0959804922004282"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.07.012","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0\/1 resection of RAS wild-type colorectal cancer liver metastases \u2013 The PARLIM trial (AIO KRK 0314)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}